**Name of Journal: *World Journal of Hypertension***

**ESPS Manuscript NO: 29857**

**Manuscript Type: Original Article**

***Observational Study***

**Association between G-protein β3 subunit gene and isolated SBP elevation of greater than 130 mmHg: A large-scale cross-sectional study in the Japanese population**

Eto M *et al.* *GNB3* and isolated SBP elevation

**Masahiko Eto, Taro Takeshima, Masanori Harada, Shinji Fujiwara, Maki Kumada, Toyomi Kamesaki, Kazuhiro Takamura, Tsuneaki Kenzaka, Yoshikazu Nakamura, Takanori Aonuma, Masanobu Okayama, Eiji Kajii**

**Masahiko Eto,** Department of Internal Medicine, Wakuya Medical and Welfare Center, Wakuya 987-0121, Miyagi, Japan

**Taro Takeshima, Maki Kumada, Toyomi Kamesaki, Eiji Kajii,** Division of Community and Family Medicine, Center for Community Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan

**Masanori Harada,** Department of Support of Rural Health Care, Yamaguchi Grand Medical Center, Hofu 747-8511, Yamaguchi, Japan

**Shinji Fujiwara,** Mima City National Health Insurance Koyadaira Clinic, Mima 777-0302, Tokushima, Japan

**Kazuhiro Takamura,** Department of Community Medicine, Obstetrics and Gynecology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 880-8510, Japan

**Tsuneaki Kenzaka,** Division of Community Medicine and Career Development, Kobe University Graduate School of Medicine, Kobe 652-0032, Hyogo, Japan

**Tsuneaki Kenzaka,** Department of Internal Medicine, Hyogo Prefectural Kaibara Hospital, Tamba 669-3395, Hyogo, Japan

**Yoshikazu Nakamura,** Department of Public Health, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan

**Takanori Aonuma,** Department of Surgery, Wakuya Medical and Welfare Center, Wakuya 987-0121, Miyagi, Japan

**Masanobu Okayama,** Division of Community Medicine and Medical Education, Kobe University Graduate School of Medicine, Kobe 652-0032, Hyogo, Japan

**Masanobu Okayama,** Division of Community and Family Medicine, Center for Community Medicine, Jichi Medical University, Shimotsuke 329-0498, Tochigi, Japan

**Author contributions:** Eto M, Takeshima T, Harada M, Fujiwara S, Kumada M, Kamesaki T, Takamura K, Kenzaka T, Nakamura Y, Aonuma T, Okayama M and Kajii E contributed to study conception and design; Eto M, Takeshima T, Harada M, Kumada M, Kamesaki T, Takamura K, Kenzaka T and Okayama M contributed to data acquisition, data analysis and interpretation, and writing of article; Eto M, Nakamura Y, Aonuma T, Okayama M and Kajii E contributed to editing, reviewing and final approval of article.

**Supported by** The Jichi Medical University 21st Century Center of Excellence Program from Minister Education, Culture, Sports, Science and Technology in Japan.

**Institutional review board statement:** The study was approved by the Jichi Medical University Epidemiological and Ethical Committee.

**Informed consent statement:** Written informed consent was obtained from all the individuals prior to their entry into this study.

**Conflict-of-interest statement:** None.

**Data sharing statement:** None.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to: Masanobu Okayama, MD, PhD**, Division of Community Medicine and Medical Education, Kobe University Graduate School of Medicine, 2-1-5 Arata-sho, Hyogo-ku, Kobe 652-0032, Hyogo, Japan. okayama@jichi.ac.jp

**Telephone:** +81-78-3826732

**Fax:** +81-78-3826283

**Received:** August 28, 2016

**Peer-review started:** August 29, 2016

**First decision:** November 21, 2016

**Revised:** January 10, 2017

**Accepted:** February 10, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To investigate whether *GNB3* C825T single nucleotide polymorphism (SNP) contributes to systolic blood pressure (SBP) ≥ 130 mmHg in a large-scale cross-sectional study among the Japanese population with diastolic blood pressure (DBP) < 85 mmHg.

***METHODS***

We analyzed 11008 Japanese subjects, including 2797 cases (SBP ≥ 130 and DBP ˂ 85 mmHg) who were not taking anti-hypertensive medication and 8211 controls (SBP ˂ 130 and DBP ˂ 85 mmHg), all of whom enrolled in the genome banking project of the 21st Century COE (Center of Excellence) Program at Jichi Medical University. Subjects were divided into four groups according to gender (male and female) and age (≤ 49 years and ≥ 50 years). *GNB3* gene polymorphism was determined using the TaqMan probe method. We compared the frequencies of alleles and genotypes between cases and controls by chi-squared test. The strength of the associations was estimated by odds ratios (ORs) and 95% confidence intervals by using logistic regression analysis. The ORs were adjusted for age and body mass index.

***RESULTS***

Allele and genotype distributions significantly differed between cases and controls only in males aged ≤ 49 years. Compared to the CC genotype, a significant OR was obtained in the TT genotype among males aged ≤ 49 years.

***CONCLUSION***

This study indicates that the TT genotype of the *GNB3* C825T SNP may contribute to SBP elevation of greater than 130 mmHg compared to the CC genotype in Japanese males aged ≤ 49 years.

**Key words:** Prehypertension; Hypertension; G-protein β3 subunit gene; Single nucleotide polymorphism

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The association of *GNB3* gene polymorphism with hypertension has been examined in different populations. Unfortunately, the reported results have been controversial. This large-scale cross-sectional study of the Japanese population clarifies that among males aged ≤ 49 years, the TT single nucleotide polymorphism of *GNB3* C825T is significantly associated with high systolic blood pressure (≥ 130 mmHg). Therapeutic intervention is recommended at this level of SBP to prevent cardiovascular disease and its progression to hypertension. This approach is likely to be more effective for youngsters, compared to the elderly. This study suggests that using genetic information could make this approach more effective.

Eto M, Takeshima T, Harada M, Fujiwara S, Kumada M, Kamesaki T, Takamura K, Kenzaka T, Nakamura Y, Aonuma T, Okayama M, Kajii E. Association between G-protein β3 subunit gene and isolated SBP elevation of greater than 130 mmHg: A large-scale cross-sectional study in the Japanese population. *World J Hypertens* 2017; In press

**INTRODUCTION**

Blood pressure (BP) is a quantitative phenotype and has a continuous distribution[1,2]. Essential hypertension (HT) is the upper part of the distribution. HT is a dichotomous trait and is defined as a BP level ≥ 140/90 mmHg. HT is one of the most important risk factors for stroke, cardiovascular disease (CVD) and end-stage renal disease (ESRD), and is a leading cause of morbidity and mortality. However, the level at which BP starts causing end-stage organ damage is thought to be lower than 140/90 mmHg. An earlier intervention to reduce BP is beneficial in the absence of cardiovascular disease. Several population-based prospective studies have indicated that a linear and impressive increase in the risk for CVD starts at a BP level ≥ 120/80 mmHg[3-7]. On the basis of these findings, the seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC-7 in 2003) introduced the term “prehypertension” as a BP category, which is defined as BP levels of 120 to 139/80 to 89 mmHg. Prehypertension (Pre-HT) includes two different subcategories: Stage 1 pre-HT (120 to 129/ 80 to 84 mmHg) and stage 2 pre-HT (130 to 139/ 85 to 89 mmHg)[8]. Since the JNC-7 proposal, numerous studies including Multiple Risk Factor Intervention Trial (MRFIT), the Framingham Heart Study, and the TRial of Preventing Hypertension (TROPHY) study have investigated the risk of pre-HT for various types of adverse outcomes. As a result, different effects of two BP ranges in pre-HT patients on future outcomes have been demonstrated[5,6,9-11]. Per the guidelines provided by the Japanese Society of Hypertension (JSH) in 2009, the target level of BP control was less than 130/85 mmHg in young and middle-aged individuals. Nowadays, therapeutic lifestyle interventions such as weight loss, salt restriction, and exercise are recommended, especially at SBP levels ≥ 130 mmHg to prevent cardiovascular disease and its progression to HT, although drug intervention is recommended at SBP ≥ 140 mmHg. HT is a multi-factorial disorder caused by the interaction between genetic and environmental factors. Many studies have sought to identify genetic variants linked to HT, but there have been few studies to correlate genetic variants with isolated SBP elevation ≥ 130 mmHg.

Heterotrimeric G-proteins, which consist of three subunits (α, β and γ), are located on the cytoplasmic side of the cell membrane and relay signals from G protein-coupled receptors (GPCRs) to downstream effectors[12,13]. In humans, there are at least 16, 5, and 12 different genes encoding α, β and γsubunits, respectively[15-18]. The combinations of the three subunits affect the function of G-proteins[14]. The *GNB3* gene is one of the five genes encoding the G-protein β subunit. Although the C825T single nucleotide polymorphism (SNP) within exon 10 of *GNB3* does not change the encoded amino acid (ser275ser), the 825T allele expresses a truncated splice variant of Gβ3, termed Gβ3s, which contains 41 fewer amino acids[14,17,19,20]. The missing domain is the functionally important region that forms tight binding with γ subunit. Gβ3s effect original downstream transduction by forming a functional heterodimer with Gγ5[14,17,19,20].

Since the first report by Siffert *et al*[14] showing a significant association between the *GNB3* 825T allele and HT, numerous studies have investigated the role of this SNP in HT. However, some studies have reported conflicting results and controversial conclusions exist[21-31]. An explanation for this discrepancy may be that the effects of *GNB3* SNP on BP are small and require large sample sizes to be detectable. In addition, few association studies have examined the effect of *GNB3* C825T SNP on the risk of SBP elevation ≥ 130 mmHg. Moreover, because of ethnic divergence of gene SNPs, it is important to construct a database of SNPs related to HT in different ethnic groups. In this study, we used a large-scale population-based database (*n* = 21004) constructed by Jichi Medical University. The aim of this study was to investigate whether the *GNB3* C825T SNP contributes to SBP ≥ 130 mmHg in a large-scale cross-sectional study among the Japanese population with DBP < 85 mmHg.

**MATERIALS AND METHODS**

***Ethical considerations***

This is a large-scale cross-sectional study for the assessment of the association between *GNB3* SNP (C825T, rs6489738) and SBP elevation of greater than 130 mmHg among a Japanese population. Written informed consent was obtained from all individuals before their participation. This study was approved by the Jichi Medical University Epidemiological and Ethical Committee.

***Recruitment of participants***

This study is based on the data from the genome banking project of the 21st Century COE (Center of Excellence) Program “Development of Frontier Medical Science in the Field of Community Medicine” at Jichi Medical University. In brief, this project recruited a total of 21004 Japanese people aged ≥ 20 years living in 78 rural and suburban areas of 30 prefectures across Japan from June 2004 to March 2008. Among the 11008 enrolled Japanese subjects, 2797 cases (SBP ≥ 130, DBP < 85 and not taking anti-hypertensive medication) and 8211 controls (SBP < 130, DBP < 85) participated in this study.

***Physical examination***

Blood pressure was measured using a standard mercury sphygmomanometer on the right arm after at least 5 min of rest in a sitting position. The first and fifth Korotkoff sounds were considered the SBP and DBP, respectively. In this study, newly diagnosed cases were defined as SBP higher than or equal to 130 mmHg and DBP less than 85 mmHg. The cases currently taking anti-hypertensive medication at the time of the study or with a history of HT were excluded. The controls were defined as SBP less than 130 mmHg and DBP less than 85 mmHg. Height and weight of the subjects were obtained from health-checkup records or medical records. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared: Weight (kg)/[height (m) × height (m)].

***Genotyping of SNP***

Venous blood was collected in 5-mL tubes containing 50 mmol/L ethylenediaminetetraaceticacid (EDTA) as anticoagulant. Genomic DNA (50-100 μL) was extracted from the peripheral blood mononuclear cells (PBMCs) of centrifuged blood using a Puregene DNA Purification Kit (Gentra Systems, Inc., Minneapolis, MN, United States). Genotyping for the SNP (C825T, rs 6489738) on G-protein β-3 subunit gene (*GNB3*) was carried out by the TaqMan probe method. Probes and primer mixtures were selected from a commercial database for the TaqMan probe system (myScience: Applied Biosystems, Foster City, CA, United States). Genomic DNA (0.5 μg) was applied to a 384-well plate and air-dried for use as templates for the reaction. The polymerase chain reaction (PCR) mixture contained 2.5 μL of probe mix and the same amount of Master Mix solution (Applied Biosystems). The standard thermocycle parameter provided by the manufacturer was used. An ABI 7900HT apparatus (Applied Biosystems) was used for reaction, genotype calling, and data exporting. The procedure for SNP genotyping was carried out at Jichi Medical University.

***Statistical analysis***

Subjects were divided into four subgroups based on their gender (male and female) and the age (≤ 49 years and ≥ 50 years). Statistical analyses were performed for each subgroup. Unless otherwise specified, continuous variables such as age and BMI are expressed as mean ± SD. Allele frequencies were determined by gene counting method. The chi-squared test was used to determine whether the genotype distributions differed from the expected from Hardy-Weinberg equilibrium (HWE). HWE was applied to the control and case population to evaluate the data quality. The differences in genotype frequencies between cases and controls were compared with a chi-squared test or Fisher’s test using 2 × 3 tables. Odds ratios (ORs) with 95% confidence intervals (95%CI) were computed to estimate associations between genotypes and SBP ≥ 130 mmHg using logistic regression analysis with adjustment for age and BMI as covariates. Results were considered to be statistically significant if a *P*-value was less than 0.05 or if a 95%CI did not include unity. All statistical analyses were carried out using IBM SPSS for Windows version 20 (IBM Inc., New York, NY, United States). The prevalence of cases defined as SBP ≥ 130 and DBP < 85 mmHg was different between subjects ≤ 49 and ≥ 50 years in both males and females. Thus, statistical analyses were performed in four subgroups (males ≤ 49 years, males ≥ 50 years, females ≤ 49 years, and females ≥ 50 years), respectively. The genotype distributions within each subgroup were consistent with Hardy-Weinberg equilibrium.

**RESULTS**

Table 1 presents demographic characteristics of the study subjects. Subjects were defined as cases if SBP ≥ 130 and DBP < 85 mmHg and defined as controls if SBP < 130 and DBP < 85 mmHg. The mean age, BMI, SBP, and DBP of the cases were significantly higher than those of the controls in all subgroups stratified by gender and age (≤ 49 years, ≥ 50 years), except for the mean age of males aged 49 years or below.

Table 2 shows the distribution of allele and genotype frequencies of the *GNB3* SNP rs 6489738 (C825T). There were no deviations from Hardy-Weinberg equilibrium in all cases and in all controls among the gender/age sub-categories (*P* > 0.18 in all cases, *P* > 0.50 in all controls). Comparison of allele and genotype distributions between cases and controls revealed that *GNB3* C825T SNP was significantly (*P* = 0.008) associated with the prevalence of SBP ≥ 130 mmHg among males aged 49 years or below, but not in other subgroups.

Table 3 shows the multivariable logistic regression analysis. Compared to the CC genotype, the odds ratio of the TT genotype for SBP ≥ 130 mmHg was significantly higher in males aged 49 years or younger. Significance was maintained even after adjusting for age and BMI. Significant probability values for the C825T SNP were obtained by a recessive model.

**DISCUSSION**

In this large-scale cross-sectional study, we confirmed that a C825T SNP on *GNB3* was associated with isolated SBP elevation ≥ 130 mmHg in Japanese males aged 49 years or younger. Definition of cases was SBP ≥ 130 and DBP < 85 mmHg and that of controls was SBP ˂ 130 and DBP < 85 mmHg. Our population–based large samples did not include cases undergoing anti-hypertensive treatment or with a history of HT. All cases were newly diagnosed as isolated systolic pre-HT or isolated systolic HT. In this study, statistical analyses were performed in four subgroups (males ≤ 49 years, males ≥ 50 years, females ≤ 49 years, and females ≥ 50 years). No significant association of this SNP with isolated SBP elevation ≥ 130 mmHg was detected, except for the subgroup of males ≤ 49 years, in which individuals homozygous for the T allele had a significantly higher risk for isolated SBP ≥ 130 mmHg, but individuals heterozygous for the T allele did not show significantly higher risk when compared to the CC genotype. The effect on blood pressure was thought to be influenced by the number of 825T alleles. In other words, this recessive effect of 825T allele suggests that a single copy of 825C allele is sufficient to attenuate BP raising-effect of the 825T allele or that the direct effect of the 825T allele on BP is small, although the shorter product (Gβ3s) of the *GNB3* 825T allele is associated with enhanced activation of heterotrimeric G-proteins compared with the product(Gβ3) of the 825C alleles[14]. Recently, the association of *GNB3* C825T with control, pre-HT, and HT subjects was examined in a Greek population (*n* = 330), but no statistical difference in the genotype frequencies was found among the three groups[32]. We were able to confirm significant association of the 825T allele with isolated SBP ≥ 130 mmHg by using a large-scale database. The frequencies of the T allele in total subjects among subgroups of males ≤ 49 years, males ≥ 50 years, females ≤ 49 years, and females ≥ 50 years were 50.8%, 50.9%, 50.3% and 50.3%, respectively. The frequencies of the 825T allele in control subjects were 49.6%, 50.8%, 50.1% and 50.5%, respectively. According to previous reports, the frequencies of the 825T allele differed significantly among different ethnic groups: 25%-31.7% in Germans[14,22,33,34], 30% in Irish (Belfast)[31], 31% in French[31], 45.6%-53.1% in Japanese[2,24-26,28,30,35], 50.1% in Canadian Sandy Lake Oji-Cree[36], 74.5% in African Americans[29], and 79% in Black Africans[37]. The 825T allele frequencies in the Japanese population of the present study were compatible with those in previous reports. The genotype distributions of total subjects (cases plus controls) within each subgroup were consistent with Hardy-Weinberg equilibrium (*P* > 0.61). The possibility of selection bias was low in males ≤ 49 years of this study. It is of interest that the BP raising-effect of the 825T allele was limited to males ≤ 49 years.

There have been no reports regarding the associations between *GNB3* C825T and the risk of SBP ≥ 130 mmHg in a Japanese population. This is the first study demonstrating a significant association between *GNB3* C825T and the risk of SBP ≥ 130 mmHg in young Japanese males. There have been several studies regarding the associations between *GNB3* C825T and HT in Japanese populations[24-28,30]. In these studies, hypertensive cases were selected as SBP ≥ 160 and/or DBP ≥ 95 mmHg[26,28], SBP ≥ 140 and/or DBP ≥ 90 mmHg[24,25,30],or SBP ≥ 134 and/or DBP ≥ 79 mmHg by ambulatory blood pressure monitoring (ABPM)[26]. The subjects taking anti-hypertensive medication were included as cases. Normotensive controls were defined as SBP ˂ 140 and DBP < 90 mmHg[24-28,30], except in one study in which the criteria of controls were SBP ˂ 134 and DBP < 79 mmHg by ABPM[26]. Although Izawa *et al*[25] demonstrated a significant association between *GNB3* C825T and HT only in males (mean age 56.3 years), the *GNB3* genotype distribution did not significantly differ between cases and controls in the analyses of all subjects. In this study, newly diagnosed cases were defined as SBP higher than or equal to 130 mmHg and DBP less than 85 mmHg. In addition, subjects taking anti-hypertensive medication at the time of the study or with a history of HT were excluded. Therefore, the different definitions of hypertension might affect the conclusions about the relationship between *GNB3* and HT. The findings in this study were obtained by using a large sample sized genome banking data collected from all over Japan. These results suggest that the *GNB3* C825T SNP is a likely risk factor for pre-HT in Japanese young males.

There was an interesting report (*n* = 447) regarding the association between *GNB3* 825T allele and SBP values in young adult Canadian Oji-Cree population[36]. The frequency of the 825T allele of the subjects was 50.1%, which is similar to the population in this study. However, the presence of the 825T allele was associated with lower SBP in young males and females, essentially making this a normotensive study sample of aboriginal people. The authors explained that functional impact of the *GNB3* 825T allele may differ according to age and, furthermore, that the impact could be different when HT has become an established phenotype. We hypothesize that there may be an interaction between the 825T allele and subjects’ lifestyle, especially with low salt intake. In our population, differences in salt intake among subgroups might affect the onset of isolated SBP ≥ 130 mmHg. In future studies, the interaction of *GNB3* C825T SNP and lifestyle, such as salt-intake, alcohol habits, and obesity must be explored.

Some limitations need to be noted when considering the results from this study. First, logistic regression analysis was adjusted only for age and BMI as covariates. We need to reassess the interactions in combination with other potential confounding factors (such as environmental factors). Second, the cross-sectional design does not allow us to make any conclusive statements. A significant association between *GNB3* C825T and isolated SBP elevation ≥ 130 mmHg in males aged ≤ 49 years needs to be reassessed in a prospective cohort study.

**ACKNOWLEDGEMENTS**

The present analysis was performed as a part of Jichi Medical School 21st Century COE (Center of Excellence) Program “Development of Frontier Medical Science in the Field of Community Medicine”. We would like to thank study participants, the members of the Jichi Community Genetics Team, the staff members of Jichi Medical University, and related facilities.

**COMMENTS**

***Background***

Heterotrimeric G-proteins, which consist of three subunits (Gα, Gβ and Gγ)~~,~~ relay signals from G protein-coupled receptors (GPCRs) to downstream effectors. GPCRs activation by agonist-binding induces conformational changes and results in the dissociation of Gαβγ into Gα and Gβγ, both of which initiate distinct downstream signaling cascades. In humans, there are at least 16, 5, and 12 different genes coding α, β, and γ subunits, respectively. The combination of αβγ affects the function of G-protein. Essential hypertension(HT) display enhanced signal transduction through pertussis toxin(PTX)-sensitive G proteins (Gi), of which G-Protein β3 subunit gene (*GNB3*) single nucleotide polymorphism (SNP, C825T) was reported by Siffert *et al* in 1998. The 825T allele is associated with the generation of a short splice variant termed G-βs, which has been proposed to lead to enhanced signal transduction by forming a functional heterodimer with Gγ5. Since first report by Siffert *et al* showing a significant association between the 825T allele and HT, numerous studies have investigated the association between the 825T allele and HT or blood pressure(BP) levels. However, the results have been conflicting to date, especially in non-whites. Moreover, it was unclear whether the 825T allele is associated with earlier blood pressure elevation, especially preHT. In addition, the frequency of the 825T allele showed the ethnic or regional diversity. Thus, it was thought to be important to construct a large-scale database of SNP in different ethnic groups. In this study, the possible effect of *GNB3* SNP (C825T) on the risk of systolic BP of greater than 130 mmHg was examined by using a large-scale Japanese population-based database (*n* = 21004) constructed by Jichi Medical University.

***Research frontiers***

A previous study reported that the GNB3-systolic BP associations was more evident among subjects with lower sodium intake/excretion, but not with higher intake/excretion. There was the possibility that higher salt intake masks the potential effect of GNB3 on BP levels. The differences in salt intake should be considered. In addition, the interaction between *GNB3* C825T SNP and other lifestyle, such as alcohol habits, and obesity must be explored. The T allele is in almost complete linkage disequilibrium with other polymorphisms within the *GNB3* gene. The mechanism by which *GNB3* C825T or the “T haplotype” increases renal sodium transport remains to be determined. The 825TT humans expressing the Gβ3-s might show a general increase in cAMP levels in renal tubular cells, due to an enhanced signaling effect, when compared to 825CC individuals. An increase in cAMP levels in the renal tubular cells would have the effect of altering the expression of channels such as aquaporin or epithelial sodium channels (ENaC). A mild alteration in the expression of these channels would lead to alterations in the salt concentrations of blood. Further studies are needed to precisely define the biochemical mechanisms by which enhanced G-protein signaling may contribute to BP elevation.

***Innovations and breakthroughs***

The frequency of the 825T allele shows the ethnic or regional diversity. In addition, the effect on blood pressure by the 825T alleles is small. If sample size is small, the higher frequency of 825T allele in Japanese may hamper the detection of the potential association. The authors could detect a significant association in M ≤ 49 by using large scale database. In addition, it is of interest that BP raising-effect by the 825 T allele was limited to M ≦ 49. The sex and age-specific analyses should be performed when the prevalence of cases are different among subgroups.

***Applications***

The different definitions of HT might affect the conclusions about the relationship between *GNB3* C825T and HT.

***Peer-review***

This is an appealing study which emphasize that GNB3 C825T polymorphism may be a useful genetic marker for hypertension.

**REFERENCES**

1 **Pickering G**. Normotension and hypertension: the mysterious viability of the false. *Am J Med* 1978; **65**: 561-563 [PMID: 707514 DOI: 10.1016/0002-9343(78)90839-2]

2 **Katsuya T**, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. *Hypertens Res* 2003; **26**: 521-525 [PMID: 12924618 DOI: 10.1291/hypres.26.521]

3 **Ninomiya T**, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Tsuruya K, Sueishi K, Tsuneyoshi M, Iida M, Kiyohara Y. Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama Study. *J Am Soc Nephrol* 2007; **18**: 2135-2142 [PMID: 17582160 DOI: 10.1681/ASN.2007010067]

4 **Lewington S**, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet* 2002; **360**: 1903-1913 [PMID: 12493255 DOI: 10.1016/S0140-6736(02)11911-8]

5 **Vasan RS**, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, Levy D. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med* 2001; **345**: 1291-1297 [PMID: 11794147 DOI: 10.1056/NEJMoa003417]

6 **Vasan RS**, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. *Lancet* 2001; **358**: 1682-1686 [PMID: 11728544]

7 **Lawes CM**, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, MacMahon S. Blood pressure and cardiovascular disease in the Asia Pacific region. *J Hypertens* 2003; **21**: 707-716 [PMID: 12658016]

8 **Chobanian AV**, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; **289**: 2560-2572 [PMID: 12748199 DOI: 10.1001/jama.289.19.2560]

9 **Neaton JD**, Kuller L, Stampler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. In: Laragh JH, Brenner BM, eds.Hypertension: pathophysiology, diagnosis and management. 2nd ed. Vol.1. New York: Raven Press, 1995: 127-144

10 **Julius S**, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. *N Engl J Med* 2006; **354**: 1685-1697 [PMID: 16537662 DOI: 10.1056/NEJMoa060838]

11 **Selassie A**, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM. Progression is accelerated from prehypertension to hypertension in blacks. *Hypertension* 2011; **58**: 579-587 [PMID: 21911708 DOI: 10.1161/HYPERTENSIONAHA.111.177410]

12 **Hofmann KP**, Scheerer P, Hildebrand PW, Choe HW, Park JH, Heck M, Ernst OP. A G protein-coupled receptor at work: the rhodopsin model. *Trends Biochem Sci* 2009; **34**: 540-552 [PMID: 19836958 DOI: 10.1016/j.tibs2009.07.005]

13 **Vilardaga JP**, Agnati LF, Fuxe K, Ciruela F. G-protein-coupled receptor heteromer dynamics. *J Cell Sci* 2010; **123**: 4215-4220 [PMID: 21123619 DOI: 10.1242/jcs.063354]

14 **Siffert W**, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. *Nat Genet* 1998; **18**: 45-48 [PMID: 9425898 DOI: 10.1038/nq0198-45]

15 **Hurowitz EH**, Melnyk JM, Chen YJ, Kouros-Mehr H, Simon MI, Shizuya H. Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes. *DNA Res* 2000; **7**: 111-120 [PMID: 10819326 DOI: 10.1093/dnares/7.2.111]

16 **Khan SM**, Sleno R, Gora S, Zylbergold P, Laverdure JP, Labbé JC, Miller GJ, Hébert TE. The expanding roles of Gβγ subunits in G protein-coupled receptor signaling and drug action. *Pharmacol Rev* 2013; **65**: 545-577 [PMID: 23406670 DOI: 10.1124/pr.111.005603]

17 **Siffert W**. G protein beta 3 subunit 825T allele, hypertension, obesity, and diabetic nephropathy. *Nephrol Dial Transplant* 2000; **15**: 1298-1306 [PMID: 10978382 DOI: 10.1093/ndt/15.9.1298]

18 **Downes GB**, Gautam N. The G protein subunit gene families. *Genomics* 1999; **62**: 544-552 [PMID: 10644457 DOI: 10.1006/geno.1999.5992]

19 **Sondek J**, Bohm A, Lambright DG, Hamm HE, Sigler PB. Crystal structure of a G-protein beta gamma dimer at 2.1A resolution. *Nature* 1996; **379**: 369-374 [PMID: 8552196 DOI: 10.1038/379369a0]

20 **Ruiz-Velasco V**, Ikeda SR. A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. *Physiol Genomics* 2003; **13**: 85-95 [PMID: 12595577 DOI: 10.1152/physiolgenomics.00057.2002]

21 **Sartori M**, Semplicini A, Siffert W, Mormino P, Mazzer A, Pegoraro F, Mos L, Winnicki M, Palatini P. G-protein beta3-subunit gene 825T allele and hypertension: a longitudinal study in young grade I hypertensives. *Hypertension* 2003; **42**: 909-914 [PMID: 14557282 DOI: 10.1161/01]

22 **Hengstenberg C**, Schunkert H, Mayer B, Döring A, Löwel H, Hense HW, Fischer M, Riegger GA, Holmer SR. Association between a polymorphism in the G protein beta3 subunit gene (GNB3) with arterial hypertension but not with myocardial infarction. *Cardiovasc Res* 2001; **49**: 820-827 [PMID: 11230982 DOI: 10.1016/S0008-6363(00)00292-3]

23 **Snapir A**, Heinonen P, Tuomainen TP, Lakka TA, Kauhanen J, Salonen JT, Scheinin M. G-protein beta3 subunit C825T polymorphism: no association with risk for hypertension and obesity. *J Hypertens* 2001; **19**: 2149-2155 [PMID: 11725157]

24 **Shioji K**, Kokubo Y, Mannami T, Inamoto N, Morisaki H, Mino Y, Tagoi N, Yasui N, Iwaii N. Association between hypertension and the alpha-adducin, beta1-adrenoreceptor, and G-protein beta3 subunit genes in the Japanese population; the Suita study. *Hypertens Res* 2004; **27**: 31-37 [PMID: 15055253 DOI: 10.1291/hypres.27.31]

25 **Izawa H**, Yamada Y, Okada T, Tanaka M, Hirayama H, Yokota M. Prediction of genetic risk for hypertension. *Hypertension* 2003; **41**: 1035-1040 [PMID: 12654703 DOI: 10.116/01.HYP.0000065618.56368.24]

26 **Ishikawa K**, Imai Y, Katsuya T, Ohkubo T, Tsuji I, Nagai K, Takami S, Nakata Y, Satoh H, Hisamichi S, Higaki J, Ogihara T. Human G-protein beta3 subunit variant is associated with serum potassium and total cholesterol levels but not with blood pressure. *Am J Hypertens* 2000; **13**: 140-145 [PMID: 10701813 DOI: 10.1016/S0895-7061(99)00118-1]

27 **Hayakawa T**, Takamura T, Abe T, Kaneko S. Association of the C825T polymorphism of the G-protein beta3 subunit gene with hypertension, obesity, hyperlipidemia, insulin resistance, diabetes, diabetic complications, and diabetic therapies among Japanese. *Metabolism* 2007; **56**: 44-48 [PMID: 17161225 DOI: 10.1016/i.metabol.2006.08.020]

28 **Kato N**, Sugiyama T, Morita H, Kurihara H, Yamori Y, Yazaki Y. G protein beta3 subunit variant and essential hypertension in Japanese. *Hypertension* 1998; **32**: 935-938 [PMID: 9822456 DOI: 10.1161/01.HYP.32.5.935]

29 **Larson N**, Hutchinson R, Boerwinkle E. Lack of association of 3 functional gene variants with hypertension in African Americans. *Hypertension* 2000; **35**: 1297-1300 [PMID: 10856280 DOI: 10.1161/01.HYP.35.6.1297]

30 **Suwazono Y**, Kobayashi E, Uetani M, Miura K, Morikawa Y, Ishizaki M, Kido T, Nakagawa H, Nogawa K. G-protein beta3 subunit variant C825T is a risk factor for hypertension in Japanese females--a prospective cohort study over 5 years. *Ann Hum Genet* 2006; **70**: 767-777 [PMID: 17044851 DOI: 10.1111/j.1469-1809.2006.00284.X]

31 **Brand E**, Herrmann SM, Nicaud V, Ruidavets JB, Evans A, Arveiler D, Luc G, Plouin PF, Tiret L, Cambien F. The 825C/T polymorphism of the G-protein subunit beta3 is not related to hypertension. *Hypertension* 1999; **33**: 1175-1178 [PMID: 10334807 DOI: 10.1161/01.HYP.33.5.1175]

32 **Maniotis C**, Chantziara K, Kokkoris P, Papadogiannis D, Andreou C, Tsioufis C, Vaiopoulos G, Stefanadis C. The AGT and the GNB3 polymorphisms and insulin resistance in prehypertension. *Hormones* (Athens) 2014; **13**: 79-86 [PMID: 24722130]

33 **Benjafield AV**, Jeyasingam CL, Nyholt DR, Griffiths LR, Morris BJ. G-protein beta3 subunit gene (GNB3) variant in causation of essential hypertension. *Hypertension* 1998; **32**: 1094-1097 [PMID: 9856980 DOI: 10.1161/01.HYP.32.6.1094]

34 **Beige J**, Hohenbleicher H, Distler A, Sharma AM. G-Protein beta3 subunit C825T variant and ambulatory blood pressure in essential hypertension. *Hypertension* 1999; **33**: 1049-1051 [PMID: 10205246 DOI: 10.1161/01.HYP.33.4.1049]

35 **Yamagishi K**, Tanigawa T, Cui R, Tabata M, Ikeda A, Yao M, Shimamoto T, Iso H. G-protein beta-3 subunit C825T polymorphism, sodium and arterial blood pressure: a community-based study of Japanese men and women. *Ann Hum Genet* 2006; **70**: 759-766 [PMID: 17044850 DOI: 10.1111/j.1469-1809.2006.00276.x]

36 **Hegele RA**, Harris SB, Hanley AJ, Cao H, Zinman B. G protein beta3 subunit gene variant and blood pressure variation in Canadian Oji-Cree. *Hypertension* 1998; **32**: 688-692 [PMID: 9774364 DOI: 10.1161/01.HYP.32.4.688]

37 **Siffert W**, Forster P, Jöckel KH, Mvere DA, Brinkmann B, Naber C, Crookes R, Du P Heyns A, Epplen JT, Fridey J, Freedman BI, Müller N, Stolke D, Sharma AM, Al Moutaery K, Grosse-Wilde H, Buerbaum B, Ehrlich T, Ahmad HR, Horsthemke B, Du Toit ED, Tiilikainen A, Ge J, Wang Y, Rosskopf D. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. *J Am Soc Nephrol* 1999; **10**: 1921-1930 [PMID: 10477144]

**P-Reviewer:** Tan XR, Wang YD **S-Editor:** Ji FF **L-Editor: E-Editor:**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 1 Characteristics of the subjects** | | | | | | | | |
|  | | | | | | | | |
|  |  | Male | | | Female | | | |
|  |  | Cases  mean ± SD | Controls  mean ± SD | *P*-value1 | Cases  mean ± SD | Controls  mean ± SD | *P*-value1 |
| Age ≤ 49 yr | | *n* = 390 | *n* = 1423 |  | *n* = 256 | *n* = 2917 |  |
|  | Age, yr | 37.9 ± 7.8 | 37.6 ± 7.7 | 0.53 | 41.4 ± 7.1 | 36.7 ± 8.0 | < 0.001 |
|  | BMI, kg/m2 | 24.4 ± 3.3 | 23.2 ± 3.1 | < 0.001 | 23.7 ± 4.4 | 21.5 ± 3.1 | < 0.001 |
|  | SBP, mmHg | 135.2 ± 6.9 | 114.7 ± 8.9 | < 0.001 | 135.3 ± 6.4 | 109.4 ± 10.1 | < 0.001 |
|  | DBP, mmHg | 77.6 ± 5.2 | 71.1 ± 7.7 | < 0.001 | 76.2 ± 6.5 | 66.7 ± 8.2 | < 0.001 |
| Age ≥ 50 yr | | *n* = 925 | *n* = 1675 |  | *n* = 1226 | *n* = 2196 |  |
|  | Age, yr | 66.9 ± 9.8 | 63.3 ± 9.7 | < 0.001 | 67.0 ± 9.7 | 61.8 ± 9.1 | < 0.001 |
|  | BMI, kg/m2 | 23.3 ± 3.0 | 22.7 ± 3.0 | < 0.001 | 23.0 ± 3.4 | 22.3 ± 2.9 | < 0.001 |
|  | SBP, mmHg | 138.7 ± 8.8 | 115.3 ± 9.5 | < 0.001 | 139.4 ± 9.6 | 114.1 ± 10.0 | < 0.001 |
|  | DBP, mmHg | 76.6 ± 6.1 | 70.5 ± 7.8 | < 0.001 | 75.2 ± 6.7 | 68.8 ± 8.0 | < 0.001 |
| 1*t*-test. DBP: Diastolic blood pressure; BMI: Body mass index; SBP: Systolic blood pressure. | | | | | | | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table 2 Allele and genotype frequencies of *GNB3* in the gender/age sub-categories** | | | | | | | | |
|  | | | | | | | | |
|  |  | Male | | | Female | | | |
|  |  | Cases  *n* (%) | Controls  *n* (%) | *P*-value1 | Cases  *n* (%) | Controls  *n* (%) | *P*-value1 |
| Age ≤ 49 yr | |  |  |  |  |  |  |
| Allele | |  |  |  |  |  |  |
|  | C825 (wild) | 350 (44.9) | 1433 (50.4) | 0.007 | 244 (47.7) | 2912 (49.9) | 0.33 |
|  | T825 (variant) | 430 (55.1) | 1413 (49.6) | 268 (52.3) | 2922 (50.1) |
| Genotype | |  |  |  |  |  |  |
|  | CC | 85 (21.8) | 356 (25.0) | 0.008 | 60 (23.4) | 718 (24.6) | 0.50 |
|  | CT | 180 (46.2) | 721 (50.7) | 124 (48.4) | 1476 (50.6) |
|  | TT | 125 (32.1) | 346 (24.3) | 72 (28.1) | 723 (24.8) |
| HWE | | *χ*² = 1.76, *P* = 0.19 | *χ*² = 0.26, *P* = 0.61 |  | *χ*² = 0.22, *P* = 0.64 | *χ*² = 0.42, *P* = 0.52 |  |
| Age ≥ 50 yr | |  |  |  |  |  |  |
| Allele | |  |  |  |  |  |  |
|  | C825 (wild) | 903 (48.8) | 1649 (49.2) | 0.78 | 1229 (50.1) | 2175 (49.5) | 0.63 |
|  | T825 (variant) | 947 (51.2) | 1701 (50.8) | 1223 (49.9) | 2217 (50.5) |
| Genotype | |  |  |  |  |  |  |
|  | CC | 221 (23.9) | 412 (24.6) | 0.92 | 309 (25.2) | 537 (24.5) | 0.88 |
|  | CT | 461 (49.8) | 825 (49.3) | 611 (49.8) | 1101 (50.1) |
|  | TT | 243 (26.3) | 438 (26.1) | 306 (25.0) | 558 (25.4) |
| HWE | | *χ*² = 0.01, *P* = 0.94 | *χ*² = 0.36, *P* = 0.55 |  | *χ*² = 0.01, *P*=0.91 | *χ*² = 0.02, *P* = 0.89 |  |
| 1*χ*² test. HWE: Hardy-Weinberg equilibrium. | | | | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 3 Associations between genotypes of *GNB3* and SBP ≥ 130 mmHg** | | | | | |
|  | | | | | |
|  |  | Male | | Female | |
|  |  | Crude OR (95%CI) | Adjusted OR (95%CI)1 | Crude OR (95%CI) | Adjusted OR (95%CI)1 |
| Age ≤ 49 yr | |  |  |  |  |
|  | CC | 1.00 | 1.00 | 1.00 | 1.00 |
|  | CT | 1.05 (0.78-1.39) | 1.09 (0.81-1.45) | 1.01 (0.73-1.39) | 1.01 (0.73-1.41) |
|  | TT | 1.51 (1.11-2.07) | 1.53 (1.11-2.10) | 1.19 (0.83-1.70) | 1.13 (0.78-1.63) |
| Age ≥ 50 yr | |  |  |  |  |
|  | CC | 1.00 | 1.00 | 1.00 | 1.00 |
|  | CT | 1.04 (0.85-1.27) | 1.01 (0.82-1.24) | 0.96 (0.81-1.15) | 1.02 (0.85-1.22) |
|  | TT | 1.03 (0.83-1.30) | 1.03 (0.81-1.30) | 0.95 (0.78-1.16) | 1.01 (0.82-1.24) |
| 1Logistic regression analysis with adjustment for age and body mass index. | | | | | |